Sorry, our fall testing
program has closed.

Be sure to check back Fall 2020
for more information.

Criteria for Testing:

In order for a horse to be considered for enrollment, we request the following:

  • Only new cases suspected of PPID (not previously diagnosed)
  • Patients currently being administered medical therapy for PPID are excluded, except horses being administered compounded pergolide
  • Patient should exhibit one or more early or advanced clinical signs as described in the EEG PPID Recommendations

Clinical Signs:

Early Clinical Signs:
  • Change in attitide/lethargy
  • Decreased performance
  • Regional hypertrichosis
  • Delayed hair coat shedding
  • Loss of topline muscle
  • Abnormal sweating (increased or decreased)
  • Infertility
  • Desmitis/tendonitis
  • Regional adiposity
  • Laminitis

Advanced Clinical Signs:
  • Dull attitide/altered mentation
  • Excercise intolerence
  • Generalized hypertrichosis
  • Loss of seasonal hair coat shedding
  • Topline muscle atrophy
  • Rounded abdomen
  • Abnormal sweating (increased or decreased)
  • Polyuria/polydipsia
  • Recurrent Infections
  • Dry eye / recurrent corneal ulcers
  • Infertility
  • Increased mammary gland secretions
  • tendon and suspensory ligament laxity
  • Regional adiposity (bulging supraorbital fat)
  • Laminitis/recurrent sole abscesses

Get Started:

  • Identify up to two horses in your practice that you would like to request tests for based on the above criteria.
    1. Complete an enrollment form for each horse (next page)
    2. Complete the Cornell submission form (sent in enrollment follow up e-mail)
    3. Prepare your sample shipments. For each horse, include:
      1. Completed Cornell submission form
      2. Tube containing plasma
      3. Cold pack

Please contact Boehringer Ingelheim Customer Care at 888-637-4251 or

NOTE: Enrollment and submission forms from past years will not be accepted during this promotion period.

Resting insulin
For the assessment of resting insulin do not feed grain within 4 hours of testing. See feeding instructions in reference section prior to pulling blood sample for resting insulin. Please follow normal management practices (leave on hay and/or pasture) except no grain should be consumed within 4 hours of pulling blood sample submitted for insulin levels.

Boehringer Ingelheim Animal Health USA Inc. reserves the right to end or modify the program, in whole or in part, at any time without notice. The program is available to only practicing veterinarians with valid veterinary-client patient relationships.

Enrollment Form

Important safety information

PRASCEND is for use in horses only. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. Weight loss, lack of energy and behavioral changes also may be observed. If severe, a temporary dose reduction may be necessary. PRASCEND has not been evaluated in breeding, pregnant or lactating horses and may interfere with reproductive hormones in these horses. Using PRASCEND at the same time as drugs known as dopamine antagonists should be avoided. These drugs may diminish the effectiveness of PRASCEND. If your horse is especially sensitive to pergolide mesylate or similar products, PRASCEND should not be used. Refer to the package insert for complete product information.


1Donaldson MT, McDonnell SM, Schanbacher BJ, et al. Variation in plasma adrenocorticotriopic hormone concentration and
dexamethasone suppression test results with season, age and sex in healthy ponies and horses. J Vet Intern Med